To determine which easily available clinical factors are associated with mortality in patients with stable COPD and if health-related quality of life (HRQoL) provides additional information.
INTRODUCTION
Forced expiratory volume in the first second (FEV 1 ) is a cornerstone for the management of chronic obstructive pulmonary disease (COPD). It is essential not only for diagnosing the disease but also for establishing its severity, as reflected in guidelines for the management of COPD. 1, 2 Several studies have also demonstrated that FEV 1 is related to disease prognosis. 3, 4 Other variables such as dyspnea, 5 body mass index (BMI), 6 previous hospitalization, 7 or exercise capacity 8 have emerged as prognostic factors. Recently, Cote and Celli summarized the literature on currently known predictors of mortality in COPD . 9 Grouping some of these factors into indices, such as the BODE index, appears to offer better prognostic power than FEV 1 , 10 but relevant predictors may be missing. Moreover, to improve the use of these predictive models, they need to include variables that are easily gathered in busy clinical practices. Although health-related quality of life (HRQoL) has been shown to be an independent predictor of mortality in patients with COPD, 11 not all HRQoL measurement instruments appear to behave in the same way. 12 Few studies have compared St. George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Questionnaire (CRQ) for assessing prognosis in COPD patients. The objectives of this study were to determine which factors used in daily clinical practice were predictive of mortality among patients with stable COPD and the relative importance of each, with the final goal being the future development of a multidimensional measure based on these clinical factors. We also aimed to determine whether HRQoL predicted mortality in this population and whether the two instruments for measuring HRQoL in patients with COPD behaved differently from each other.
METHODS

Study Design and Sample
Between February 1998 and February 1999, we recruited all patients previously diagnosed with COPD who were under the age of 80 and who regularly visited outpatient clinics affiliated with a teaching hospital that has a catchment area of 300,000 inhabitants. All patients with COPD have to be seen by their pulmonary specialist between 1 to 4 times per year. Those who fulfilled the selection criteria were interviewed in-person when attending their pulmonary visit. All patients were followed for a period of three years by telephone and were interviewed inperson 5 years after the start of the study. The study was approved by the Research Committee of the Hospital Galdakao-Usansolo, and all patients provided verbal informed consent as required.
Patients were included in the study consecutively if they had been diagnosed with COPD at least six months previously and had been under treatment at the hospital's outpatient facilities for at least six months. Patients had to be stable (no increase in respiratory symptoms or changes in treatment) for six weeks prior to inclusion. Other inclusion criteria were FEV 1 <80% of the predicted value, with an FEV 1 /FVC quotient <70%, and a negative bronchodilation test with FEV 1 change <200 ml and under 15% of the baseline value. The functional parameters used are those obtained following bronchodilation. Patients were not eligible for the study if they had been diagnosed with asthma, had extensive pulmonary tuberculosis or neoplastic processes, were suffering from psychiatric or neurological problems that might prevent effective collaboration, or had hearing or other problems that impeded accurate communication. Patients over the age of 80 were excluded given the potential difficulty of members of this age group to reliably provide the measurements required for this study.
Measures
Patients were asked about their level of dyspnea using a 5-point scale, adapted from Fletcher:
13 1="dyspnea only with intense and strenuous exercise", 2="capable of walking at the same pace as other people of my age on the level", 3="capable of walking on the level at my own speed without dyspnea, but incapable of walking at the same pace as persons of my own age", 4="dyspnea after walking slowly for 100 meters" and 5="dyspnea when resting or after slight effort such as getting dressed". Dyspnea was also assessed using a 10-cm visual analogue scale (VAS) with values from 0 to 100 points, where 0 represented absence of dyspnea and 100 maximum dyspnea. Number of pack-years was calculated by the product of years as a smoker and average number of cigarettes smoked per day, divided by 20, and body mass index (BMI) by dividing weight in kilograms by the square of height in meters. Comorbidities were determined by reviewing the patients' clinical histories. Spirometry was conducted following criteria from the American Thoracic Society (ATS) 14 and Spanish Information on all patients' hospital admissions due to COPD exacerbation in the 2 years prior to their inclusion in the study was obtained by analyzing the database for our hospital, which is the benchmark hospital for these patients. In the unusual case of a patient having been admitted to another center, admission forms were used to establish the reason for admission. Vital status was determined initially by telephone interviews to all patients. All reported deaths and dates of deaths were confirmed by reviewing medical reports or examining of the hospital database and public death registries, or both. Deaths were considered confirmed if the record matched the subject on name, sex and date of birth. The cause of death was based on the hospital reports and public death registries. When death occurred out of hospital, researchers carried out a telephone survey of relatives and the primary care doctor. Later, the research team analyzed all data and established the causes of death.
Statistical Analysis
We present mean and standard deviations for continuous variables and frequencies and percentages for categorical variables. We used the Chi-Square and Fisher's exact tests to evaluate associations among categorical variables. To study the bivariate relationship between vital status at 5 years and potential predictor variables, we used Student's t-test and the Wilcoxon test for continuous variables and Chi-Square and Fisher exact tests for categorical variables.
Logistic regression and Cox proportional hazard models were used in the multivariate analysis to assess the relationship between mortality and clinical and demographic variables. All-cause and respiratory-related mortality were used as dependent variables, in separate analyses. We selected independent variables that had a statistically significant association with vital status (p<0.05) and added each independent variable to the model separately. We then added the overall SGRQ and CRQ questionnaire scores separately to the above models. We also studied the significance of the SGRQ and CRQ questionnaire scores when the categorical dyspnea variable was removed from the models. For easier interpretation of the results, age, tobacco packs/year, FEV 1% , total SGRQ and total CRQ were estimated as a 10-unit improvement. Finally, we evaluated the variables that measured dyspnea categorically (a four-level variable was created after collapsing level 4 and 5 of the 5-point rating scale) and continuously (using a VAS scale) to determine if they had different associations with mortality.
Bootstrapping methods were performed in order to evaluate the internal validity of the final multivariate models. The S-PLUS 2000 statistical program was used to perform these calculations.
We computed the C statistic using logistic regression models to study the contribution of each variable to the final predictive model. In these analyses, the C statistic is a mathematical function of the sensitivity and specificity of our score in classifying patients by means of a logistic regression model as either dying or surviving. The null value for the C statistic is 0.5, with a maximum value of 1.0 (higher values indicating better health). We started by performing a stepwise procedure; then estimated the C statistics for each variable by introducing them into the model, one by one.
All effects were considered significant at p<0.05, unless otherwise noted. All statistical analyses were performed using SAS for Windows statistical software, version 8.2. (SAS Institute, Inc., Carey, NC).
RESULTS
Of the 729 patients of the initial cohort, 63 were excluded because they were older than 80 years 27 patients had cancer, 11 patients had sensorial problems, six patients had dementia and 11 had diseases, which made it difficult to measure the different tests for the study. A total of 611 COPD patients (98% men) were included in the study. Their characteristics are presented in Table 1 . After 5 years of follow-up, 166 (27%) patients had died-81 (13%) as a result of exacerbation of their baseline disease (COPD) and 16 (3%) of other respiratory causes. Forty (6.5%) died of cardiovascular or cerebrovascular causes, 26 (4%) of other causes, mainly neoplasms; no cause of death was recorded for 3 patients. The survival rates at 1, 3, and 5 years were 96%, 85%, and 73%, respectively. Table 1 compares the baseline characteristics of those surviving and those who died over the five years of the study. Deceased patients were significantly older, had worse FEV 1% , higher degree of dyspnea, hospitalized for COPD more often in the 2 years prior to the study, and smoked more. Healthrelated quality of life (HRQoL) results for patients who died during the study period were consistently poorer at baseline than for those who survived (Table 2) .
Baseline Characteristics
Multivariate Analysis
In the logistic regression models, the variables that were independently related to both respiratory and all-cause mortality were FEV 1% , dyspnea (5-point Fletcher scale with ratings of 4 and 5 collapsed to give 4 levels), age, hospitalizations in the 2 previous years, and lifetime pack-years of smoking (Table 3) .
Baseline HRQoL, measured by either the disease specific or the SF-36 questionnaires, were not associated with mortality in the multivariate models. However, when dyspnea was excluded from the model, HRQoL measured by total SGRQ score (OR, 0.98; 95% CI, 0.96-0.99; p=0.002) and total CRQ score (OR 1.01; 95% CI, 1.01-1.02; p=0.03) proved to be independently associated with respiratory and all-cause mortality. When dyspnea was included in the logistic regression model using the VAS, it was not associated with respiratory (OR, 0.99; 95% CI, 0.98-1.01) or all-cause mortality (OR 1.00; 95% CI, 0.99-1.01). In these models, total SGRQ (OR, 0.98; 95% CI, 0.96-0.99) and total CRQ (OR, 1.01; 95% CI, 1.00-1.02) scores were related to respiratory mortality. BMI did not correlate with mortality in either the univariate or any of the multivariate analyses, nor did comorbidities when grouped or taken individually. where 1=dyspnea only with intense and strenuous exercise, 2=capable of walking at the same pace as other people of my age on the level, 3= capable of walking on the level at my own speed without dyspnea, but incapable of walking at the same pace as persons of my own age, 4= dyspnea after walking slowly for 100 meters, and 5=dyspnea when resting or after slight effort such as getting dressed. Because of small numbers in level 4 and 5, these levels were collapsed to create four categories. VAS dyspnea values from 0 to 100 points, the greater the value, the worse the dyspnea ‡ Over the prior two years § Comorbidity was assessed as mean number of co morbidities/patient When we evaluated survival using a proportional hazard model, we found the same results that have been described previously (Online-Appendix 1). To internally validate the final multivariate models we performed bootstrapping calculations of our estimates (Online-Appendix 2). The bootstrap results did not differ substantially from the original results.
The variables in order of importance to explain respiratoryrelated mortality were FEV 1% (C statistic 0.73), followed by dyspnea, age, previous hospitalization, and pack-years of smoking. For all-cause mortality, age (0.72) and dyspnea (0.65) occupied first and second place as mortality predictors, followed by FEV 1% , previous hospitalization due to COPD exacerbation, and lifetime pack-years of smoking .
DISCUSSION
In patients with stable COPD, we found that several easily obtained clinical variables-FEV 1% , dyspnea, age, prior hospitalizations for exacerbations of COPD, and pack-years of cigarette smoking-were associated with respiratory and allcause and mortality. In contrast, HRQoL was not associated with respiratory or all-cause and mortality. Our study has several strengths compared to prior studies. We followed a larger number of patients (n=611) over a 5-year period and assessed key variables found to be associated with COPDrelated mortality in smaller studies. We also used three measures of HRQoL and assessed the internal validity of our results using bootstrap methods.
The 5-year mortality rate in our population was 26%, which is comparable with mortality rates observed in studies of similar design. 5, 8, 11, 24 The relatively low mortality rate is likely due to the fact that patients were recruited from outpatient clinics, not from hospitals settings 25 where mortality rates can be up to 49% at 2 years. 26 FEV 1% had the strongest association with mortality in our study, a relationship that has been observed in other studies. 3, 4 Dyspnea was the second most important factor independently related to respiratory mortality and was the most important factor associated with of all-cause mortality. This relationship has varied among prior studies. In one study, dyspnea was more predictive than FEV 1% in evaluating mortality after 5 years. 5 In other studies, however, dyspnea did not predict mortality.
11
In our study, the number of severe COPD exacerbations requiring hospitalization and life time pack-years of smoking increased the risk of respiratory and all-cause mortality. Our results are congruent with recently published studies. 7, 24, 27, 28 Whether co-morbidities are predictors of mortality among patients with COPD remains controversial. We did not observe an association between number of comorbidities, much as Domingo-Salvany et al. found. 11 However, Almagro et al., using the Charlson index, did observe comorbidities to be associated with mortality. 24 Soler et al., 7 using the same index, showed no association between comorbidities and mortality. More importantly, although BMI <20 kg/m 2 has been associated with COPD-related mortality, 6 we did not find that it was associated with mortality. This may be due to the small number of patients with BMI <20 kg/m 2 in our study (n=26).
HRQoL, as measured by SGRQ and SF-36 questionnaires, has been linked both to respiratory and all-cause mortality. 8, 11 In contrast, we did not find scores on these questionnaires to be independently related to mortality once they had been adjusted for other variables, particularly dyspnea as measured 11 Several studies discuss the usefulness of instruments such as VAS for measuring dyspnea during exercise. 29 However, to the best of our knowledge, no study compares VAS with other dyspnea scales such as Fletcher's scale 13 or the MRC scale 30 in clinically stable patients. Dyspnea scales such as the MRC scale, which is similar to the one used in our study, have been shown to be useful in COPD severity classification and in establishing prognosis. 5, 31 The VAS may not have the same utility, base on our study results. This may be due to the fact that the VAS method, measuring from 0 to 100, may be more difficult to be understand by patients than specific descriptions of dyspnea chosen from a rating scale. In fact, when we used a VAS to measure dyspnea, dyspnea was no longer independently related with mortality, but HRQoL was as independently associated with mortality.
No published studies have directly compared the two disease specific HRQoL measures, St. George's Respiratory Questionnaire and Chronic Respiratory Questionnaire, as predictors of respiratory mortality. One study found that CRQ did not successfully predict mortality in a cohort of COPD patients. 12 In our study, neither of the two questionnaires was independently associated with respiratory mortality. However, when we excluded dyspnea from the model or included it as VAS, both questionnaires were independently associated with respiratory and all-cause mortality and their capacity as a predictor of mortality was quite similar. This is largely driven by the fact that dyspnea is a key determinant of HRQoL, as has been demonstrated in other studies. 32, 33 Our study adds to previous prognostic studies of COPD patients. From the clinical perspective, busy clinicians, especially in primary care settings, are not likely to measure exercise capacity and calculate the BODE index. They need easy methods for predicting mortality. All of our variables are readily available to clinicians caring for COPD patients. From the research perspective, our study contributes to the literature in several ways. First, we directly assessed the added value of measuring HRQOL, using three different tools, to see if any of them adds anything beyond the clinical factors. When dyspnea is included, HRQoL appears to be less important as a predictor of mortality. Second, we assess dyspnea by using two different measurement methods, rating and visual analog (VAS) scales. From our data, it seems that rating scales are the preferred method.
Our study has several limitations. We did not assess for changes in any of the main independent variables (e.g., dyspnea, FEV1, HRQoL) to determine if changes in these variables were associated with mortality. Second, the patient population was almost entirely comprised of men. This reflects the current distribution of COPD in Spain, 7, 11 where women did not begin to smoke until late in the 20th century. Although the high percentage of men does not reflect a selection bias or affect the validity of the results, it does limit their generalizability to women. Finally, we focused on variables that are easy to obtain in daily clinical practice. We did not include others, such as the exercise capacity or the presence of pulmonary hypertension, that without any doubt have prognostic ability but are more difficult to obtain Several clinical variables including FEV 1% and dyspnea are strongly associated with respiratory and all-cause mortality among patients with stable COPD. Age, previous hospitalizations due to COPD exacerbation, and lifetime pack-years of smoking are also important in establishing the prognosis of COPD. Subsequent studies of new multifactorial predictive modes using these simple measures should be developed. In contrast, two respiratory-specific HRQoL measures, the SGRQ and CRQ, were not independently related to mortality, or survival, when dyspnea was taken into account.
